Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087009 | 0.95 | SIGMAR1 (0.37) | SLC6A2SLC6A4SIGMAR1TMEM97EBP | |
| SCHEMBL18909605 | 0.84 | SLC6A2 (0.33) | SLC6A2SLC6A4SIGMAR1TMEM97EBP | |
| SCHEMBL15086957 | 0.84 | SIGMAR1 (0.35) | SLC6A2SLC6A4SIGMAR1TMEM97EBP | |
| SCHEMBL17426068 | 0.84 | SLC6A2 (0.33) | SLC6A2SLC6A4SIGMAR1TMEM97EBP | |
| SCHEMBL18904829 | 0.82 | SLC6A2 (0.34) | SLC6A2SLC6A4SIGMAR1TMEM97EBP | |
| SCHEMBL21101599 | 0.81 | SLC6A2 (0.34) | SLC6A2SLC6A4SIGMAR1TMEM97EBP | |
| SCHEMBL18909626 | 0.78 | SLC6A2 (0.30) | SLC6A2SLC6A4 | |
| SCHEMBL15171151 | 0.77 | LSS (0.40) | SIGMAR1 | |
| SCHEMBL23469783 | 0.73 | — | — | |
| SCHEMBL18909608 | 0.72 | KDM4E (0.42) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | SLC6A2 4429/4885SLC6A4 3849/4885SIGMAR1 4355/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | SLC6A2 4429/4885SLC6A4 3849/4885SIGMAR1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.